| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | An E. coli-derived human protein (amino acids K23-K561) was used as the immunogen for the FAM129B antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
FAM129B/Niban-like protein 1 (family with sequence similarity 129, member B) belongs to a poorly characterized family of Niban proteins that also includes FAM129A/Niban and FAM129C/Niban-like protein 2. FAM129A/Niban is implicated in the ER stress response and is upregulated at the protein level in thyroid carcinoma. FAM129C/Niban-like protein 2 is preferentially expressed in B-cells and is one of five biomarkers upregulated in whole blood from patients with colorectal carcinoma. FAM129B is broadly expressed and has been shown to be a downstream target of B-Raf in melanoma cells. Though FAM129B does not appear to regulate cell growth and division, phosphorylation of FAM129B by B-Raf is essential for the invasive potential of melanoma and non-melanoma cell lines. Deletion of FAM129B in melanoma cells significantly impairs B-Raf/MEK/Erk-dependent invasion into the extracellular matrix.
This anti-FAM129B antibody is supplied as Antigen affinity purified (Rabbit, Polyclonal (rabbit origin), Rabbit IgG, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.
Key elements and design rationale
- Target: FAM129B
- Format: Antigen affinity purified
- Localization: Cytoplasmic
- Species reactivity: Human
- Applications (listed): WB, IHC-P, FACS, Direct ELISA
- Conjugate: Unconjugated
- Clone and antibody class: Polyclonal (rabbit origin), Rabbit IgG
Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.
Biological background
FAM129B is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.
Research relevance and current trends
- Profiling FAM129B expression across model systems, perturbations, and time points to support mechanistic hypotheses.
- Combining antibody-based detection with multi-omics or imaging readouts to link FAM129B signal with phenotype.
- Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.
Common research applications
- WB
- IHC-P
- FACS
- Direct ELISA
Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.
Notes for experimental interpretation
- Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
- Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
- Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.